pembrolizumabRecent, repeatedEvidence- NCT07807163 · Bicara Therapeutics · Phase 2 · live · background · “Pembrolizumab (KEYTRUDA®)” · registered Aug 2026
- NCT07744126 · AbbVie · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07668154 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Jun 2026
- NCT07662720 · Glycyx Therapeutics · Phase 2 · live · background · “Pembolizumab” · registered Jun 2026
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 2125 studies | 1721 studies | background 37 · comparator 1 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07744126 · AbbVie · Phase 2 · live · comparator · “Carboplatin” · registered Jul 2026
- NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “Carboplatin” · registered Jul 2026
- NCT07668154 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 2 · live · background · “carboplatin” · registered Jun 2026
- NCT07276399 · Johnson & Johnson · Phase 3 · live · background · “Carboplatin” · registered Dec 2025
- NCT07059221 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Carboplatin / Cisplatin” · registered Jul 2025
| Eli Lilly and Company16% of its industry studies | 1011 studies | 1314 studies | background 22 · comparator 4 |
CetuximabRecent, repeatedEvidence- NCT07768189 · Corbus Pharmaceuticals Inc. · Phase 3 · live · comparator · “Cetuximab (EGFR inhibitor)” · registered Aug 2026
- NCT07435324 · R-Pharm · Phase 3 · comparator · “Erbitux®” · registered Feb 2026
- NCT07059221 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Cetuximab” · registered Jul 2025
- NCT06943820 · Akeso · Phase 2 · live · background · “Cetuximab” · registered Apr 2025
- NCT06194656 · sinopharm · Phase 2 · live · background · “Cetuximab injection” · registered Dec 2023
| Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004) | 99 studies | 99 studies | comparator 10 · background 16 |
CisplatinRecent, repeatedEvidence- NCT07744126 · AbbVie · Phase 2 · live · comparator · “Cisplatin” · registered Jul 2026
- NCT07668154 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 2 · live · background · “Cisplatin” · registered Jun 2026
- NCT07435324 · R-Pharm · Phase 3 · background · “Cisplatin” · registered Feb 2026
- NCT07276399 · Johnson & Johnson · Phase 3 · live · comparator · “Cisplatin” · registered Dec 2025
- NCT07059221 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Carboplatin / Cisplatin” · registered Jul 2025
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 88 studies | 1212 studies | background 26 · comparator 6 |
PaclitaxelRecent, repeatedEvidence- NCT06727565 · Gilead Sciences · Phase 2 · live · background · “Paclitaxel” · registered Dec 2024
- NCT06699212 · Rakuten Medical, Inc. · Phase 3 · live · comparator · “Paclitaxel” · registered Aug 2024
- NCT06535607 · AstraZeneca · Phase 2 · live · background · “Paclitaxel” · registered Jul 2024
- NCT06385080 · Johnson & Johnson · Phase 2 · live · background · “Paclitaxel” · registered Apr 2024
- NCT06378177 · Lyvgen Biopharma Holdings Limited · Phase 2 · live · background · “Paclitaxel injection” · registered Apr 2024
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 77 studies | 1010 studies | comparator 3 · background 16 |
DocetaxelRecent, repeatedEvidence- NCT07768189 · Corbus Pharmaceuticals Inc. · Phase 3 · live · comparator · “Docetaxel” · registered Aug 2026
- NCT07435324 · R-Pharm · Phase 3 · background · “Docetaxel” · registered Feb 2026
- NCT06943820 · Akeso · Phase 2 · live · background · “Docetaxel” · registered Apr 2025
- NCT06699212 · Rakuten Medical, Inc. · Phase 3 · live · comparator · “Docetaxel” · registered Aug 2024
- NCT05910827 · Hummingbird Bioscience · Phase 2 · live · background · “Docetaxel” · registered Jun 2023
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 55 studies | 99 studies | comparator 5 · background 11 |
FluorouracilRecent, repeatedEvidence- NCT07744126 · AbbVie · Phase 2 · live · comparator · “Fluorouracil” · registered Jul 2026
- NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “5-fluorouracil” · registered Jul 2026
- NCT06943820 · Akeso · Phase 2 · live · background · “5-FU (5-fluorouracil)” · registered Apr 2025
- NCT06699212 · Rakuten Medical, Inc. · Phase 3 · live · comparator · “5-fluorouracil” · registered Aug 2024
- NCT06535607 · AstraZeneca · Phase 2 · live · background · “5-FU” · registered Jul 2024
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 55 studies | 88 studies | background 15 · comparator 4 |
FulvestrantRecent, repeatedEvidence- NCT07109726 · Terremoto Biosciences Inc. · Phase 2 · live · background · “Fulvestrant injection” · registered Jul 2025
- NCT06993844 · Ensem Therapeutics · Phase 2 · live · background · “ETX-636 dose escalation in combination with fulvestrant” · registered May 2025
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Fulvestrant” · registered Mar 2023
- NCT05226871 · Pfizer · Phase 2 · live · background · “Fulvestrant” · registered Jan 2022
- NCT03169764 · ImmunityBio, Inc. · Phase 2 · background · “fulvestrant” · registered May 2017
| AstraZeneca70% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 1 generic authorized | 44 studies | 44 studies | background 5 |
NivolumabRecent, repeatedEvidence- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
- NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Nivolumab” · registered Feb 2022
- NCT05027204 · CSPC Pharmaceutical Group Limited · Phase 2 · background · “Nivolumab” · registered Aug 2021
- NCT04180371 · BicycleTx Limited · Phase 2 · live · background · “Nivolumab” · registered Nov 2019
- NCT03645928 · Iovance Biotherapeutics, Inc. · Phase 2 · background · “Nivolumab” · registered Aug 2018
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 22 studies | 44 studies | background 12 |
LetrozoleRecent, repeatedEvidence- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Letrozole” · registered Mar 2023
- NCT05226871 · Pfizer · Phase 2 · live · comparator · “Letrozole” · registered Jan 2022
| Novartis52% of its industry studiesUS: off-patent, 6 generics marketed | 22 studies | 22 studies | comparator 1 · background 1 |
enzalutamideRecent, repeatedEvidence- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Enzalutamide” · registered Jun 2023
- NCT05551117 · MacroGenics · Phase 2 · comparator · “Enzalutamide” · registered Sep 2022
| Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized | 22 studies | 11 study | background 1 · comparator 1 |
Abiraterone AcetateRecent, repeatedEvidence- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Abiraterone” · registered Jun 2023
- NCT05551117 · MacroGenics · Phase 2 · comparator · “Abiraterone” · registered Sep 2022
| Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized | 22 studies | 11 study | background 1 · comparator 1 |